U.S. News Room
June 11, 2022
Quizartinib Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy in Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
Download
June 07, 2022
DS-6000 Suggests Early Clinical Activity in Patients with Advanced Ovarian Cancer or Renal Cell Carcinoma
Download
June 05, 2022
ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease
Download
June 03, 2022
Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer
Download
May 23, 2022
Daiichi Sankyo Showcases Bold Leadership in Oncology with Survival Improvements for Certain Patients with Cancer at ASCO and EHA
Download
May 05, 2022
ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
Download
April 26, 2022
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Low Metastatic Breast Cancer
Download
April 19, 2022
ENHERTU® Granted Priority Review in the U.S. for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Download
February 21, 2022
ENHERTU® Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2 Low Metastatic Breast Cancer
Download